Emergent BioSolutions (NYSE:EBS) Upgraded by StockNews.com to “Buy” Rating

Emergent BioSolutions (NYSE:EBS) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

A number of other research analysts also recently weighed in on the company. Benchmark upped their price target on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Rodman & Renshaw reaffirmed a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research report on Friday, September 13th.

Emergent BioSolutions Stock Up 1.6 %

EBS traded up $0.14 during midday trading on Thursday, hitting $8.71. The company had a trading volume of 788,886 shares, compared to its average volume of 3,197,925. The stock’s 50 day moving average price is $9.37 and its 200 day moving average price is $8.65. Emergent BioSolutions has a 52 week low of $1.42 and a 52 week high of $15.10. The company has a market capitalization of $471.94 million, a price-to-earnings ratio of -2.12 and a beta of 1.59. The company has a quick ratio of 1.47, a current ratio of 2.88 and a debt-to-equity ratio of 1.30.

Hedge Funds Weigh In On Emergent BioSolutions

Several large investors have recently added to or reduced their stakes in EBS. SeaCrest Wealth Management LLC raised its stake in shares of Emergent BioSolutions by 3.2% in the third quarter. SeaCrest Wealth Management LLC now owns 118,700 shares of the biopharmaceutical company’s stock worth $991,000 after purchasing an additional 3,705 shares during the last quarter. Price T Rowe Associates Inc. MD raised its position in Emergent BioSolutions by 22.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 4,409 shares during the last quarter. CWM LLC raised its position in Emergent BioSolutions by 32,706.7% in the 2nd quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 4,906 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Emergent BioSolutions during the 2nd quarter worth $41,000. Finally, Verus Capital Partners LLC purchased a new position in Emergent BioSolutions during the 2nd quarter worth $68,000. Institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.